NCT06085183View on ClinicalTrials.gov

Indigotindisulfonate Sodium Injection, USP As an Aid in the Determination of Ureteral Patency in Patient's with Renal Impairment

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Ureter Injury

Interventions

OTHER

Saline Injection 0.9%

Placebo

DRUG

Indigotindisulfonate sodium 0.8%

Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.

Trial Locations (1)

12008

RECRUITING

Albany Medical Center, Albany

All Listed Sponsors

lead

Prove pharm

INDUSTRY